艾迪药业
(688488)
| 流通市值：90.89亿 | | | 总市值：90.89亿 |
| 流通股本：4.21亿 | | | 总股本：4.21亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 552,400,249.88 | 362,484,696.38 | 197,860,545.62 | 417,804,702.67 |
| 营业收入 | 552,400,249.88 | 362,484,696.38 | 197,860,545.62 | 417,804,702.67 |
| 二、营业总成本 | 538,614,945.79 | 347,182,753.38 | 178,441,372.82 | 548,682,156.97 |
| 营业成本 | 189,352,749.77 | 124,761,206.87 | 75,114,905.33 | 188,291,309.03 |
| 税金及附加 | 9,369,817.96 | 5,354,740.8 | 2,530,698.33 | 5,610,704.34 |
| 销售费用 | 187,702,249.75 | 124,403,595.73 | 57,867,148.6 | 155,032,579.3 |
| 管理费用 | 76,940,855.93 | 44,200,667.21 | 23,678,257.46 | 96,913,688.51 |
| 研发费用 | 64,999,220.3 | 41,599,388.41 | 15,711,444.19 | 89,887,129.01 |
| 财务费用 | 10,250,052.08 | 6,863,154.37 | 3,538,918.91 | 12,946,746.78 |
| 其中:利息费用 | 11,918,861.89 | 8,088,243.91 | 4,246,314.54 | 15,360,254.21 |
| 其中:利息收入 | 1,836,241.34 | 1,307,547.53 | 714,034.64 | 2,523,349.69 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 8,304,357.2 | 14,218,294.32 | 9,262,691.53 | 10,763,010.03 |
| 加:投资收益 | -319,794.61 | -568,771.59 | -225,518.4 | 6,962,716.68 |
| 资产处置收益 | 77,620.24 | 99,170.37 | - | - |
| 资产减值损失(新) | -4,756,058.36 | -2,896,425.23 | - | -65,199,313.37 |
| 信用减值损失(新) | -264,719.27 | 479,142.61 | 1,220,693.58 | 2,591,374.41 |
| 其他收益 | 11,644,656.42 | 5,471,023.85 | 2,150,673.88 | 11,294,290.52 |
| 营业利润平衡项目 | 0 | -0.01 | 0 | 0 |
| 四、营业利润 | 28,471,365.71 | 32,104,377.32 | 31,827,713.39 | -164,465,376.03 |
| 加:营业外收入 | 1,063,452.27 | 1,267,015.19 | 101,943.16 | 408,648.41 |
| 减:营业外支出 | 2,911,890.32 | 804,170.28 | 368,942.92 | 1,940,294.69 |
| 五、利润总额 | 26,622,927.66 | 32,567,222.23 | 31,560,713.63 | -165,997,022.31 |
| 减:所得税费用 | 10,511,059.43 | 6,077,751.58 | 5,950,734.51 | -27,161,932.61 |
| 六、净利润 | 16,111,868.23 | 26,489,470.65 | 25,609,979.12 | -138,835,089.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 16,111,868.23 | 26,489,470.65 | 25,609,979.12 | -138,835,089.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -6,840,499.38 | 9,190,954.53 | 15,581,976.25 | -141,204,293.98 |
| 少数股东损益 | 22,952,367.61 | 17,298,516.12 | 10,028,002.87 | 2,369,204.28 |
| 扣除非经常损益后的净利润 | -18,612,262.57 | -5,112,714.15 | 7,399,659.11 | -148,445,417.91 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | 0.02 | 0.04 | -0.34 |
| (二)稀释每股收益 | -0.02 | 0.02 | 0.04 | -0.34 |
| 九、综合收益总额 | 16,111,868.23 | 26,489,470.65 | 25,609,979.12 | -138,835,089.7 |
| 归属于母公司股东的综合收益总额 | -6,840,499.38 | 9,190,954.53 | 15,581,976.25 | -141,204,293.98 |
| 归属于少数股东的综合收益总额 | 22,952,367.61 | 17,298,516.12 | 10,028,002.87 | 2,369,204.28 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |